Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential

TSX:EDT - Post by User

Spectral Medical Inc

<< Previous

Bullboard Posts

Next >>

Post by mercedesmanon Jul 23, 2021 10:37am

153 Views

Post# 33595778

Hemopurifiers on Fire update! Comp.'s pulling ahead nicely

...since their March 2020 pandemic start, lows !

New and improved as of July 23 - lets consider recent advances !

Here's a sampling:

CTSO March 2020 low $ 4.00. Currently $ 7.46 + 86%
Tailwinds provided by: recent failed UK studies and the possibility of a new US Trial (Phase 1). MC = 4.4X Spectral's despite no Active Phase 1 Trial in NA.

ohh..and trades on Nasdaq & promotional

AEMD March 2020 lo $ 1.28. Currenlty $ 4.08 + 218%
Tailwiinds provided by: the release of some non-trial results (2 CV patients?), and the bantering around of some hemopurfusion ideas (and the frequent trading of shares). 15M shares o/s - daily volumes peaking at over 250M shares. MC =22% higher than Spectral's despite no revenues

Ohh...and trades on Nasdaq & promotional

EDT March 2020 lows .44. Currently $ .38 - 14.0 %

Tailwinds provided by:

Phase 3 B confimatory Trial (with favourable FDA parameters, rules/carryforwards)
Baxter ($ 40B USD MC) Distribution Agreement put in place 2020
FDA approved companion diagnostic (= precision medicien = the future)
De-risked Trial with $ advancements by Baxter of $ 5M USD + $ ? M USD + $ ?M USD +? for Tigris Trial
FDA approval of SAMI for US
partial FDA approval of DIMI for hospital use
Health Canada approval of DIMI
Hiring of Kellum (world KoL on blood filtration and AKI)
Latest Analyst target of over $ 3/sh with implied/stated probabilty of success on PMX of over 75%
More recent positive RWE on PMX
$ 5B+ market opportunity on the second pony trick (HHD) . Possible full FDA approval next year following a Trial to start this year.
$ 18M plus in the bank following recent financing at .425 with as yet undisclosed Mgt. rewards (options? warrants?) for great performance